JS015

BIOLOGICAL4 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Fudan University

Conditions

Advanced Colorectal CancerAdvanced Solid CancerAdvanced Solid TumorPancreatic Cancer

Phase 1

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.Advanced Solid Cancer

Start: 2023-02-01End: 2025-07-01Target: 114Updated: 2023-03-15

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

RecruitingNCT06139211

Shanghai Junshi Bioscience Co., Ltd.Advanced Solid Tumor

Start: 2024-01-03End: 2026-01-28Target: 186Updated: 2024-12-20

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruitingNCT06370754

Fudan UniversityPancreatic Cancer

Start: 2024-04-30End: 2027-04-30Target: 117Updated: 2024-04-17

Phase 2

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

RecruitingNCT06885385

Shanghai Junshi Bioscience Co., Ltd.Advanced Colorectal Cancer

Start: 2025-04-23End: 2027-02-13Target: 60Updated: 2025-06-24

Related Papers

Abstract LB212: Efficacy and safety of JS015 (an anti-dickkopf-1 antibody) in combination with standard of care in patients with gastrointestinal cancers

Cancer Research2025-04-251 citations